Immunotherapy duo aims to shrink stomach tumors before surgery

NCT ID NCT06829797

Recruiting now Disease control Sponsor: Shandong Provincial Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests whether adding an immunotherapy drug (QL1706) to standard chemotherapy before and after surgery can improve outcomes for people with locally advanced stomach or gastroesophageal junction cancer. About 96 participants will be randomly assigned to receive either the combination or chemotherapy alone. The main goal is to see if the combination leads to a higher rate of complete tumor disappearance (pathological complete response) at the time of surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Iparomlimab and tuvonralimab (QL1706) combined with SOX chemotherapy
What this could lead to: If successful, this combination could become a new standard neoadjuvant treatment, potentially improving the chance of complete tumor removal and long-term control for locally advanced gastric cancer.
What could go wrong: This is an early Phase 2 trial with only 96 participants, so results may not be definitive. Adding immunotherapy to chemotherapy can increase side effects, and the benefit over chemotherapy alone is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED GASTRIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

Contacts and locations

Locations

Shandong Provincial Hospital
RECRUITING

Jinan, Shandong, 250021, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.